Trade iTeos Therapeutics Inc - ITOS CFD

iTeos Therapeutics, Inc. Company profile

About iTeos Therapeutics Inc

iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The Company's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The Company is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.

Financial summary

BRIEF: For the nine months ended 30 September 2021, iTeos Therapeutics Inc revenues increased from $0K to $104.3M. Net income applicable to common stockholders totaled $29.6M vs. loss of $28.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Grant income increase of 80% to $8.9M (income).